Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Rhea-AI Summary

Annovis (NYSE: ANVS) priced an underwritten public offering of 7,895,000 common shares and accompanying warrants to purchase up to 7,105,500 shares at a combined price of $1.90 per share and warrant.

Gross proceeds are expected to be about $15.0 million, mainly funding buntanetap Phase 3 programs in AD and PD.

Positive

• Gross proceeds of approximately $15.0 million before fees and expenses
• Funding supports continued clinical development of lead drug buntanetap in AD and PD
• Warrants exercisable at $2.25 for six years may provide additional capital
• Offering conducted from an effective Form S-3 shelf registration, adding financing flexibility

Negative

• Issuance of 7,895,000 new common shares implies shareholder dilution
• Warrants for up to 7,105,500 additional shares could create further future dilution

News Market Reaction – ANVS

+5.15%

10 alerts

+5.15% Session close to close

+36.6% Peak Tracked

-3.1% Trough Tracked

$76.22M Market Cap

0.7x Rel. Volume

In the May 20 session, ANVS gained 5.15%, reflecting a notable positive market reaction. Argus tracked a peak move of +36.6% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.2% in the session following this news. A strong positive reaction would contrast ...

Analysis

The stock moved +5.2% in the session following this news. A strong positive reaction would contrast with ANVS’s typical response to financings, where the average move around prior offerings was about -7.05%. Any upside would likely reflect investor confidence that additional capital meaningfully extends runway for the Phase 3 buntanetap program. However, repeated equity and warrant issuance, together with past volatility around such deals, could leave the stock vulnerable if enthusiasm fades or further capital raises emerge.

Key Figures

Gross proceeds: $15.0 million Shares offered: 7,895,000 shares Warrants offered: 7,105,500 warrants +5 more

8 metrics

Gross proceeds $15.0 million Expected gross proceeds from current offering before fees, excluding warrant exercise

Shares offered 7,895,000 shares Common stock in the underwritten public offering

Warrants offered 7,105,500 warrants Accompanying warrants to purchase common stock

Offering price $1.90 per unit Combined price per share of common stock and accompanying warrant

Warrant exercise price $2.25 per share Exercise price for each warrant share

Warrant term 6 years Warrants exercisable immediately and expiring six years after issuance

Expected closing date May 21, 2026 Anticipated closing date of the offering, subject to conditions

Phase Phase 3 Development stage of buntanetap for neurodegenerative diseases

Previous Offering Reports

5 past events · Latest: 2026-04-09 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-04-09	Equity unit offering	Negative	-29.6%	Underwritten unit deal at $1.90 with warrants funding Phase 3 buntanetap.
2025-10-27	Registered direct sale	Negative	+4.9%	Registered direct common stock sale at $2.05 for $3.4M gross proceeds.
2025-10-15	Offering closing	Negative	+12.2%	Closing of $6.0M registered direct offering at $1.50 per share.
2025-10-10	Registered direct deal	Negative	-22.7%	Definitive agreements for $6M registered direct equity financing.
2025-02-04	Public equity financing	Negative	+0.0%	Closing of $21M public offering with five-year warrants at $5.00.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offering-related announcements have produced mixed reactions, with notable selloffs on some unit deals but occasional positive moves on smaller registered directs. The average move of -7.05% highlights that financings have often pressured the stock, though not uniformly.

Recent Company History

In the past year, ANVS has repeatedly used equity offerings and equity-linked securities to fund buntanetap development. Events on Feb 4, 2025, Oct 10–27, 2025, and Apr 9, 2026 raised between $3.4M and $21M via public or registered direct offerings, typically at modest prices with attached warrants. Market reactions ranged from a -29.57% drop to double-digit gains, showing inconsistent sentiment toward dilution, but today’s negative move is broadly consistent with the average downside on such news.

Key Terms

underwritten public offering, warrants, exercise price, prospectus supplement

4 terms

underwritten public offering financial

"today announced the pricing of an underwritten public offering of 7,895,000 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

warrants financial

"shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

exercise price financial

"Each warrant will be exercisable for one share of common stock at an exercise price of $2.25"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

prospectus supplement regulatory

"A final prospectus supplement and accompanying prospectus describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock, will be exercisable immediately following the issue date and will expire six years after the date of issuance.

All of the shares of common stock and the accompanying warrants are being offered by Annovis. The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering.

Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $15.0 million, excluding potential proceeds from the exercise of the warrants. The offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions.

Canaccord Genuity is acting as the sole bookrunner in the offering.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in clinical studies for Alzheimer’s disease (AD) and Parkinson’s Disease (PD) and for working capital and general corporate purposes.

The shares and the accompanying warrants are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-276814) previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the intended use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

What did Annovis (ANVS) announce in its May 20, 2026 stock offering?

Annovis announced the pricing of an underwritten public offering of common stock and warrants. According to Annovis, the deal covers 7,895,000 shares and warrants to purchase up to 7,105,500 shares, raising about $15.0 million in gross proceeds before expenses.

What is the price and size of the Annovis (ANVS) May 2026 public offering?

The offering is priced at a combined $1.90 per common share and accompanying warrant. According to Annovis, it expects to receive approximately $15.0 million in gross proceeds before underwriting discounts, commissions, and offering expenses, excluding any additional warrant exercise proceeds.

What are the warrant terms in the Annovis (ANVS) May 2026 stock offering?

Each warrant is exercisable for one Annovis common share at an exercise price of $2.25. According to Annovis, the warrants are exercisable immediately after issuance, relate to up to 7,105,500 shares, and will expire six years from their issuance date.

When is the Annovis (ANVS) May 2026 offering expected to close?

The offering is expected to close on or about May 21, 2026, subject to customary conditions. According to Annovis, Canaccord Genuity is acting as sole bookrunner, and the securities are issued under an effective Form S-3 shelf registration statement.

How will Annovis (ANVS) use the proceeds from its May 2026 stock and warrant offering?

Annovis plans to use net proceeds to advance its lead compound buntanetap in clinical studies for Alzheimer’s and Parkinson’s. According to Annovis, remaining funds will support working capital and general corporate purposes, helping sustain its Phase 3 clinical-stage operations.

What does the May 2026 Annovis (ANVS) equity offering mean for existing shareholders?

The offering adds 7,895,000 new shares and warrants for up to 7,105,500 shares, increasing share count. According to Annovis, the capital will fund buntanetap development and corporate needs, which may support the company’s programs while creating dilution for current shareholders.